Compare HHS & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HHS | MBRX |
|---|---|---|
| Founded | 1923 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 16.1M |
| IPO Year | 1994 | 2016 |
| Metric | HHS | MBRX |
|---|---|---|
| Price | $2.39 | $2.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $61.00 |
| AVG Volume (30 Days) | 3.0K | ★ 353.3K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.35 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $159,570,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.07 | $0.26 |
| 52 Week High | $4.32 | $7.98 |
| Indicator | HHS | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.24 | 38.82 |
| Support Level | $2.28 | $2.00 |
| Resistance Level | $2.94 | $2.58 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 41.67 | 13.48 |
Harte-Hanks Inc is a customer experience company. The company operates three business segments: Revenue Solutions; Customer Care; and Fulfillment & Logistics Services. It derives maximum revenue from Fulfillment & Logistics Services segment. The Fulfillment & Logistics Services segment includes printing, lettershop, advanced mail optimization (including commingling services), logistics and transportation optimization, monitoring and tracking, to support traditional and specialized mailings. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.